Table 1:

Summary of the 15 cohorts across 8 studies used in this study.

Data Set	Cohort	Description	Treatment(s)	Pre / On	# Patients	Responders	Non- Responders	REF
Gide	Gide_Pre_PD1_CTLA4	91 Samples treated with anti PD-1 or anti PD-1 CTLA4 31 Female Samples : 60 Male samples Median age = 61	Ipilimumab Nivolumab Pembrolizumab	Pre	32	21	11	25
	Gide_Pre_PD1		Pembrolizumab Nivolumab	Pre	41	19	22
	Gide_On_PD1_CTLA4		Ipilimumab Nivolumab Pembrolizumab	On	9	5	4
	Gide_On_PD1		Nivolumab Pembrolizumab	On	9	4	5
Hugo	HugoLo_IPRES_2016	26 Samples 25 Pre-anti PD1 treatment 1 On anti PD1 treatment 8 Female Samples : 18 Male Samples Median Age = 61 M Stage 21 M1c : 3 M1b : 1 M1a : 1 M0	Pembrolizumab	Pre /On	26	13	13	26
Lee	Lee_Pre	RNA seq analysis of 78 tumors from 55 patients. 28 paired pre and on treatment biopsies and 50 unpaired biopsies.	Pembrolizumab Nivolumab	Pre	43	22	21	27
	Lee_On		Pembrolizumab Nivolumab	On	35	6	29
Liu	Liu_Naive	122 Samples 51 Female : 71 Male M Stage 91 M1c : 14 M1b : 10 M0 : 7 M1a	Pembrolizumab Nivolumab	Pre	74	31	43	28
	Liu_Prog		Pembrolizumab Nivolumab	On	48	17	31
Riaz	Riaz_Pre	Patients were stratified based on whether they had received previous ICI therapy with Ipilimumab. 98 samples were then treated with Nivolumab to characterize the genomic changes of pre and post therapy.	Nivolumab	Pre	49	10	39	29
	Riaz_On		Nivolumab	On	49	10	39
Van Allen	VanAllen_antiCTLA4_2015	Patient Details Median Age = 61 13 Female : 28 Male M Stage 29 M1c : 8 M1b : 3 M1a : 1 M0	Ipilimumab	Pre	41	8	33	30
Du	Du_Pre	42 paired pre and on treatment tumor samples. 8 unpaired pre and on treatment tumor samples.	Ipilimumab Nivolumab Pembrolizumab	Pre	19	6	13	31
	Du_On		Ipilimumab Nivolumab Pembrolizumab	On	31	5	26
Lauss	Lauss	Majority of samples obtained from lymph node or subcutaneous metastases. All patients were previously treated with other immunotherapies like IL-2 and anti-CTLA4.	Adoptive T-cell therapy	Pre	25	10	15	32